Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Adma Biologics Inc shares valued at $391,860 were sold by Grossman Adam S on Jul 15 ’25. At $18.66 per share, Grossman Adam S sold 21,000 shares. The insider’s holdings dropped to 2,037,850 shares worth approximately $38.11 million following the completion of this transaction.
Before that, Grossman Adam S had sold 21,000 shares from its account. In a trade valued at $437,010, the President and CEO traded Adma Biologics Inc shares for $20.81 each. Upon closing the transaction, the insider’s holdings decreased to 21,000 shares, worth approximately $38.22 million.
Analysts at Mizuho started covering the stock with ‘”a Buy”‘ outlook in a report released in mid October. As of November 11, 2021, Raymond James has increased its “an Outperform” rating to a “Strong buy” for ADMA. Earlier on November 09, 2021, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for ADMA stock.
Analyzing ADMA Stock Performance
On last trading session, Adma Biologics Inc [NASDAQ: ADMA] rose 0.59% to $18.7. The stock’s lowest price that day was $18.59, but it reached a high of $19.025 in the same session. During the last five days, there has been a surge of approximately 8.03%. Over the course of the year, Adma Biologics Inc shares have jumped approximately 51.29%.
Support And Resistance Levels for Adma Biologics Inc (ADMA)
RSI (Relative Strength Index) is 56.09 on the 14-day chart, showing neutral technical sentiment.
Is Adma Biologics Inc subject to short interest?
Stocks of Adma Biologics Inc saw a sharp rise in short interest on 2025-07-15 jumping by 0.66 million shares to 14.47 million. Data from Yahoo Finance shows that the short interest on 2025-06-13 was 13.81 million shares. A jump of 4.59% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 4.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 4.45.
Which companies own the most shares of Adma Biologics Inc (ADMA)?
In terms of Adma Biologics Inc share price expectations, FactSet research, analysts set an average price target of 16 in the next 12 months, down nearly -13.93% from the previous closing price of $18.59. Analysts anticipate Adma Biologics Inc stock to reach 18 by 2025, with the lowest price target being 14. In spite of this, 3 analysts ranked Adma Biologics Inc stock as Buy at the end of 2025. On June 04, 2019, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $8.
